Barclays PLC Increases Stake in 89bio, Inc. (NASDAQ:ETNB)
Barclays PLC boosted its position in shares of 89bio, Inc. (NASDAQ:ETNB – Get Rating) by 1,490.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 388,982
89bio Files $500M Mixed Securities Shelf
89bio, Inc. (NASDAQ:ETNB) Short Interest Update
89bio, Inc. (NASDAQ:ETNB – Get Rating) was the recipient of a significant decrease in short interest during the month of December. As of December 30th, there was short interest totalling 4,430,000 sh
Blueprint Medicines' (BPMC) Aykavit SNDA Gets FDA Priority Tag
The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.
With Stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) Must Be Wishing They Had Bought More Last Year
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?
RBC Capital Reaffirms Their Buy Rating on 89bio (ETNB)
89bio, Inc. (NASDAQ:ETNB) CFO Sells $74,396.97 in Stock
89bio, Inc. (NASDAQ:ETNB – Get Rating) CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $12.51, fo
89bio (NASDAQ:ETNB) Trading Down 5.2% Following Insider Selling
89bio, Inc. (NASDAQ:ETNB – Get Rating) fell 5.2% on Friday following insider selling activity. The company traded as low as $11.58 and last traded at $11.58. 34,720 shares were traded during mid-day
89bio (ETNB) Receives a Buy From SVB Securities
No Stock Yet